Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen Inc. (BIIB) Laps the Stock Market: Here's Why

Biogen Inc. (BIIB) closed at $247.52 in the latest trading session, marking a +1.1% move from the prior day.

Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.

Biogen Inc. (BIIB) Rises Higher Than Market: Key Facts

Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.

Biogen Inc. (BIIB) Stock Moves -0.37%: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $245.27, moving -0.37% from the previous trading session.

Prothena's (PRTA) Update on Pipeline Progress Disappoints

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.

Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.

Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod

FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU

Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

Alzheimer's Disease Space Evolves in 2023: Stocks in Focus

The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.

Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

Stock Market News for Nov 9, 2023

U.S. stock closed mostly higher on Wednesday, with the S&P 500 and Nasdaq extending their longest winning streak in more than two years as investors weighed comments from Federal Reserve officials on future interest rates path.

Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%

Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.

Earnings Data Deluge

Earnings Data Deluge

Mark Vickery headshot

Pre-Markets Keep Streak Alive; RL, BIIB Beat

The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.

Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.